254 related articles for article (PubMed ID: 17982114)
1. Progression of prostate cancer from a subset of p63-positive basal epithelial cells in FG/Tag transgenic mice.
Reiner T; de Las Pozas A; Parrondo R; Perez-Stable C
Mol Cancer Res; 2007 Nov; 5(11):1171-9. PubMed ID: 17982114
[TBL] [Abstract][Full Text] [Related]
2. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
3. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma.
Shappell SB; Olson SJ; Hannah SE; Manning S; Roberts RL; Masumori N; Jisaka M; Boeglin WE; Vader V; Dave DS; Shook MF; Thomas TZ; Funk CD; Brash AR; Matusik RJ
Cancer Res; 2003 May; 63(9):2256-67. PubMed ID: 12727848
[TBL] [Abstract][Full Text] [Related]
4. The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089.
Perez-Stable CM; Schwartz GG; Farinas A; Finegold M; Binderup L; Howard GA; Roos BA
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):555-63. PubMed ID: 12050097
[TBL] [Abstract][Full Text] [Related]
5. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.
Gabril MY; Onita T; Ji PG; Sakai H; Chan FL; Koropatnick J; Chin JL; Moussa M; Xuan JW
Gene Ther; 2002 Dec; 9(23):1589-99. PubMed ID: 12424611
[TBL] [Abstract][Full Text] [Related]
6. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
Man YG; Gardner WA
Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
[TBL] [Abstract][Full Text] [Related]
7. Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice.
Perez-Stable C; Altman NH; Brown J; Harbison M; Cray C; Roos BA
Lab Invest; 1996 Feb; 74(2):363-73. PubMed ID: 8780156
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer progression, metastasis, and gene expression in transgenic mice.
Perez-Stable C; Altman NH; Mehta PP; Deftos LJ; Roos BA
Cancer Res; 1997 Mar; 57(5):900-6. PubMed ID: 9041192
[TBL] [Abstract][Full Text] [Related]
9. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations.
Shibata MA; Ward JM; Devor DE; Liu ML; Green JE
Cancer Res; 1996 Nov; 56(21):4894-903. PubMed ID: 8895741
[TBL] [Abstract][Full Text] [Related]
10. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
11. Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model.
Duan W; Gabril MY; Moussa M; Chan FL; Sakai H; Fong G; Xuan JW
Oncogene; 2005 Feb; 24(9):1510-24. PubMed ID: 15674347
[TBL] [Abstract][Full Text] [Related]
12. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer.
Kasper S; Smith JA
J Urol; 2004 Jul; 172(1):12-9. PubMed ID: 15201729
[TBL] [Abstract][Full Text] [Related]
13. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
[TBL] [Abstract][Full Text] [Related]
14. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.
Degl'Innocenti E; Grioni M; Boni A; Camporeale A; Bertilaccio MT; Freschi M; Monno A; Arcelloni C; Greenberg NM; Bellone M
Eur J Immunol; 2005 Jan; 35(1):66-75. PubMed ID: 15597325
[TBL] [Abstract][Full Text] [Related]
15. p63 expression profile in normal and malignant prostate epithelial cells.
Davis LD; Zhang W; Merseburger A; Young D; Xu L; Rhim JS; Moul JW; Srivastava S; Sesterhenn IA
Anticancer Res; 2002; 22(6C):3819-25. PubMed ID: 12553000
[TBL] [Abstract][Full Text] [Related]
16. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW
Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice.
Hsu CX; Ross BD; Chrisp CE; Derrow SZ; Charles LG; Pienta KJ; Greenberg NM; Zeng Z; Sanda MG
J Urol; 1998 Oct; 160(4):1500-5. PubMed ID: 9751403
[TBL] [Abstract][Full Text] [Related]
18. Bub1 up-regulation and hyperphosphorylation promote malignant transformation in SV40 tag-induced transgenic mouse models.
Guo C; Wu G; Chin JL; Bauman G; Moussa M; Wang F; Greenberg NM; Taylor SS; Xuan JW
Mol Cancer Res; 2006 Dec; 4(12):957-69. PubMed ID: 17189386
[TBL] [Abstract][Full Text] [Related]
19. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
20. Transgenic mice bearing the polyomavirus large T antigen directed by 2.1 kb of the keratin 19 promoter develop bronchiolar papillary tumors with progression to lung adenocarcinomas.
Lebel M; Webster M; Muller WJ; Royal A; Gauthier J; Mes-Masson AM
Cell Growth Differ; 1995 Dec; 6(12):1591-600. PubMed ID: 9019164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
